Syrosingopine sensitizes cancer cells to killing by metformin

Biozentrum, University of Basel, 4056 Basel, Switzerland. Basilea Pharmaceutica International Ltd., Basel, Switzerland. Institute for Medical Microbiology, University of Basel, 4003 Basel, Switzerland. Molecular Pathology, University Hospital Basel, 4003 Basel, Switzerland. Stem Cell Center of Competence, University of Basel, 4056 Basel, Switzerland. *Corresponding author. Email: m.hall@unibas.ch

[1]  P. Austin,et al.  Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis , 2017, Clinical genitourinary cancer.

[2]  T. Sharpe,et al.  Syrosingopine sensitizes cancer cells to killing by metformin , 2016, Science Advances.

[3]  S. Wild,et al.  Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. , 2016, Lung cancer.

[4]  P. Goodwin,et al.  Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. , 2016, Cell metabolism.

[5]  Sven Christian,et al.  Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? , 2016, Cell metabolism.

[6]  L. Platanias,et al.  Repurposing metformin for cancer treatment: current clinical studies , 2016, Oncotarget.

[7]  J. Kos,et al.  Gamma-enolase: a well-known tumour marker, with a less-known role in cancer , 2015, Radiology and oncology.

[8]  M. V. Heiden,et al.  Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells , 2015, Cell.

[9]  A. Zwinderman,et al.  Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2015, The Lancet. Oncology.

[10]  B. Masquida,et al.  A Moonlighting Human Protein Is Involved in Mitochondrial Import of tRNA , 2015, International journal of molecular sciences.

[11]  V. Bae-Jump,et al.  Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer , 2014, Cancer medicine.

[12]  J. Ioannidis,et al.  Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial , 2014, Diabetes Care.

[13]  M. Pollak,et al.  Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria , 2014, The Biochemical journal.

[14]  Andrea Glasauer,et al.  Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis , 2014, eLife.

[15]  I. Ben-Sahra,et al.  Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia. , 2014, Cancer letters.

[16]  Thijs J. Hagenbeek,et al.  The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. , 2013, Cancer letters.

[17]  J. Kos,et al.  C-Terminal Peptide of γ-Enolase Impairs Amyloid-β-Induced Apoptosis Through p75NTR Signaling , 2013, NeuroMolecular Medicine.

[18]  D. Braun,et al.  Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. , 2013, Methods.

[19]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.

[20]  Á. Díaz-Ramos,et al.  α-Enolase, a Multifunctional Protein: Its Role on Pathophysiological Situations , 2012, Journal of biomedicine & biotechnology.

[21]  M. Pollak.  Investigating metformin for cancer prevention and treatment: the end of the beginning. , 2012, Cancer discovery.

[22]  P. Goodwin,et al.  Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study , 2012, Breast Cancer Research and Treatment.

[23]  R. DePinho,et al.  In vitro enzymatic activity assay for ENOLASE in mammalian cells in culture , 2012 .

[24]  L. Chin,et al.  Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.

[25]  A. Farmer,et al.  Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials , 2012, Diabetologia.

[26]  A. Khurana,et al.  Metformin is synthetically lethal with glucose withdrawal in cancer cells , 2012, Cell cycle.

[27]  J. Joseph,et al.  Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. , 2012, Cancer research.

[28]  J. Kos,et al.  γ-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways. , 2012, The Biochemical journal.

[29]  Tetsuro Tsujimoto,et al.  Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis , 2012, PloS one.

[30]  P. Goodwin,et al.  Understanding the benefit of metformin use in cancer treatment , 2011, BMC medicine.

[31]  M. Capello,et al.  α‐enolase: a promising therapeutic and diagnostic tumor target , 2011, The FEBS journal.

[32]  C. Schaefer,et al.  Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction , 2011, Oncogene.

[33]  J. Kos,et al.  Gamma-1-Syntrophin Mediates Trafficking of Gamma-Enolase towards the Plasma Membrane and Enhances Its Neurotrophic Activity , 2011, Neurosignals.

[34]  Massimiliano Cazzaniga,et al.  Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis , 2010, Cancer Prevention Research.

[35]  P. Home,et al.  Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials , 2010, Diabetologia.

[36]  Jing Chen,et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.

[37]  W. Mikulits,et al.  Hepatospheres: Three dimensional cell cultures resemble physiological conditions of the liver. , 2010, World journal of hepatology.

[38]  J. Pelletier,et al.  Target identification using drug affinity responsive target stability (DARTS) , 2009, Proceedings of the National Academy of Sciences.

[39]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Donnan,et al.  New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.

[41]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[42]  I. Popovich,et al.  Metformin Decelerates Aging and Development of Mammary Tumors in HER-2/neu Transgenic Mice , 2005, Bulletin of Experimental Biology and Medicine.

[43]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[44]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[45]  A. Subramanian,et al.  Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. , 2000, The Journal of biological chemistry.

[46]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[47]  M. Murphy,et al.  Quantitation and origin of the mitochondrial membrane potential in human cells lacking mitochondrial DNA. , 1999, European journal of biochemistry.

[48]  C. Godinot,et al.  Functional F1-ATPase Essential in Maintaining Growth and Membrane Potential of Human Mitochondrial DNA-depleted ρ° Cells* , 1998, The Journal of Biological Chemistry.

[49]  J. Henry,et al.  Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. , 1994, The Journal of experimental biology.

[50]  Y. Mizuno,et al.  Synthetic peptide corresponding to 30 amino acids of the C-terminal of neuron-specific enolase promotes survival of neocortical neurons in culture. , 1994, Biochemical and biophysical research communications.

[51]  R. Edwards,et al.  Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. , 1993, The Journal of biological chemistry.

[52]  Jordi Félez,et al.  Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.

[53]  M. King,et al.  Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. , 1989, Science.

[54]  D. Scherman,et al.  Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. , 1989, Biochemistry.

[55]  T. Olofsson,et al.  Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells. , 1984, Cancer research.

[56]  J. Polak,et al.  NEURON-SPECIFIC ENOLASE IS PRODUCED BY NEUROENDOCRINE TUMOURS , 1981, The Lancet.

[57]  Y. Kohno,et al.  Selective depleting effect of syrosingopine on braib catecholamine levels with relation to morphine analgesia in the rat , 1976, Pharmacology Biochemistry and Behavior.

[58]  C. Bartels.  Syrosingopine: a new rauwolfia preparation. , 1959, The New England journal of medicine.

[59]  B. Calesnick,et al.  REDUCED SEDATIVE EFFECT OF A NEWLY SYNTHESIZED RESERPINE DERIVATIVE (SYROSINGOPINE): CLINICAL APPRAISAL IN PRIMARY HYPERTENSION , 1959, Journal of the American Geriatrics Society.

[60]  G. Chang,et al.  Surface a -Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target , 2013 .

[61]  C. Chong,et al.  Mysterious metformin. , 2009, The oncologist.